Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography

Clinics in Liver Disease

Volumn 22, Issue 1, 2018, Pages 73-92

  Tsai, Eugenia ^a   Lee, Tai Ping ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Northwell Health   (United States)

Author keywords

Nonalcoholic fatty liver disease; Noninvasive biomarker; Steatohepatitis; Transient elastography

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKERATIN 18; CYTOKERATIN 18 M65; FERRITIN; FIBROBLAST GROWTH FACTOR 21; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DEATH; CONTROLLED ATTENUATION PARAMETER; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY SCORE; EARLY DIAGNOSIS; FIBROMETER; FIBROSIS 4; HUMAN; INFLAMMATION; LIVER BIOPSY; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER STIFFNESS; NAFLD LIVER FAT SCORE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PROGNOSTIC ASSESSMENT; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STAGING; TRANSIENT ELASTOGRAPHY; BIOPSY; BLOOD; DIAGNOSTIC IMAGING; ELASTOGRAPHY; LIVER; METABOLISM; PATHOLOGY;

BIOMARKERS; BIOPSY; C-REACTIVE PROTEIN; ELASTICITY IMAGING TECHNIQUES; FERRITINS; HUMANS; KERATIN-18; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85034596741     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2017.08.004     Document Type: Review

References (138)

1. Bedongni, G., Miglioli, L., Masutti, F., et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatology 42 (2005), 44–52.
2. Bugianesi, E., Moscatiello, S., Ciaravella, M.F., et al. Insulin resistance in non-alcoholic fatty liver disease. Curr Pharm Des 16:17 (2010), 1941–1951.
3. Loomba, R., Sanyal, A., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
4. Michelotti, G.A., Machado, M.V., Diehl, A.M., NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 10 (2013), 656–665.
5. Do, A., Lim, J.K., Epidemiology of nonalcoholic fatty liver disease: a primer. Clin Liver Dis 7:5 (2016), 106–108.
6. Baffy, G., Brunt, E., Caldwell, S.H., Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 56:6 (2012), 1384–1391.
7. D'Avola, D., Labgaa, I., Villanueva, A., Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease-hepatocellular carcinoma: magnitude of the problem from a hepatology clinic perspective. Clin Liver Dis 8:4 (2016), 100–104.
8. Zezos, P., Renner, E.L., Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol 20:42 (2014), 15532–15538.
9. Malik, S.M., deVera, M.E., Fontes, P., et al. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 9 (2009), 782–793.
10. Banini BA, et al. Abstract #46. Presented at: American College of Gastroenterology Annual Scientific Meeting. Las Vegas (NV), October 14–19, 2016.
11. Fazel, Y., Koenig, A.B., Sayiner, M., et al. Epidemiology and natural history of non-alcoholic fatty liver disease. Metab Clin Exp 65:8 (2016), 1017–1025.
12. Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
13. Cusi, K., Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis 13 (2009), 545–563.
14. Adams, L.A., Feldstein, A.E., Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol 4:5 (2010), 623–635.
15. Nalbantoglu, I., Brunt, E.M., Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol 20:27 (2014), 9026–9037.
16. Brunt, E.M., Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. Dig Dis 1:30 Suppl (2012), 61–68.
17. Gaidos, J.K., Hillner, B.E., Sanyal, A.J., A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int 28 (2008), 650–658.
18. Bravo, A.A., Sheth, S.G., Chopra, S., Liver biopsy. N Engl J Med 341 (2001), 495–500.
19. Ratziu, V., Charlotte, F., Heurtier, A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128:7 (2005), 1898–1906.
20. Regev, A., Berho, M., Jeffers, L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97:10 (2002), 2614–2618.
21. Merriman, R.B., Ferrell, L.D., Patti, M.G., et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 44 (2006), 874–880.
22. Myers, R.P., Fong, A., Shaheen, A.A.M., Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 28:5 (2008), 705–712.
23. Kose, S., Ersan, G., Tatar, B., et al. Evaluation of percutaneous liver biopsy complications in patients with chronic viral hepatitis. Eur J Med 47:3 (2015), 161–164.
24. Fallatah, H.I., Noninvasive biomarkers of liver fibrosis: an overview. Adv Hepatol 2014 (2014), 1–15.
25. Machado, M.V., Cortez-Pinto, H., Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 58:5 (2013), 1007–1019.
26. Ratziu, V., Bellentani, S., Cortez-Pinto, H., et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53 (2010), 372–384.
27. Wieckowska, A., McCullough, A.J., Felstein, A.E., Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46:2 (2007), 582–589.
28. Simundic, A.M., Measures of diagnostic accuracy: basic definitions. EJIFCC 19:4 (2009), 203–211.
29. Pepe, M.S., Etzioni, R., Feng, Z., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:14 (2001), 1054–1061.
30. Poynard, T., Ratziu, V., Naveau, S., et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 4:10 (2005), 1–14.
31. Bedogni, G., Bellentani, S., Miglioli, L., et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general populations. BMC Gastroenterol 6:33 (2006), 1–7.
32. Kotronen, A., Peltonen, M., Hakkarainen, A., et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137 (2009), 865–872.
33. Bedogni, G., Kahn, H.S., Bellentani, S., et al. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 10:98 (2010), 1–8.
34. Sanal, M.G., Biomarkers in non-alcoholic fatty liver disease-the emperor has no clothes?. World J Gastroenterol 21:11 (2015), 3223–3231.
35. Shen, J., Chan, HL-Y., Wong, G.L., et al. Non-invasive diagnosis of non-alcoholic steatohepatiis by combined serum biomarkers. J Hepatol 56 (2012), 1363–1370.
36. Fitzpatrick, E., Dhawan, A., Noninvasive biomarkers in nonalcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol 20:31 (2014), 10851–10863.
37. Targher, G., Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with nonalcoholic fatty liver disease. J Hepatol 45 (2006), 879–881.
38. Musso, G., Gambino, R., Cassader, M., et al. Meta-analysis natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43 (2011), 617–649.
39. Hui, J.M., Farrell, G.C., Kench, J.G., et al. High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology 39 (2004), 1458–1459.
40. Jarrar, M.H., Baranova, A., Collantes, R., et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 27 (2008), 412–421.
41. Hui, J.M., Hodge, A., Farrell, G.C., et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 (2004), 46–54.
42. Abiru, S., Migita, K., Maeda, Y., et al. Serum cytokine and soluble cytokine receptor levels in patients with nonalcoholic steatohepatitis. Liver Int 26 (2006), 39–45.
43. Wieckowska, A., Papouchado, B.G., Li, Z., et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103 (2008), 1372–1379.
44. Ajmera, V., Perito, E.R., Bass, N.M., et al., NASH Clinical Research Network. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology 65 (2017), 65–77.
45. Pagano, C., Soardo, G., Pilon, C., et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 91:3 (2006), 1081–1086.
46. Lebensztejn, D.M., Wojtkowska, M., Skiba, E., et al. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease. Adv Med Sci 54:2 (2009), 177–182.
47. Abenavoli, L., Luigiano, C., Guzzi, P.H., et al. Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease. Panminerva Med 56:2 (2014), 189–193.
48. Shen, C., Zhao, C.Y., Wang, W., et al. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol, 14, 2014, 39.
49. Le, D., Marks, D., Lyle, E., et al. Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients. Surg Endosc 21 (2007), 1593–1599.
50. Yesilova, Z., Yaman, H., Oktenli, C., et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 100 (2005), 850–855.
51. Chalasani, N., Deeg, M.A., Crabb, D.W., Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99 (2004), 1497–1502.
52. Sanyal, A.J., Campbell-Sargent, C., Mirshahi, F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001), 1183–1192.
53. Feldstein, A.E., Wieckowska, A., Lopez, A.R., et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50 (2009), 1072–1078.
54. Wieckowska, A., Zein, N.N., Yerian, L.M., et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44 (2006), 27–33.
55. Yilmaz, Y., Dolar, E., Ulukaya, E., et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 13 (2007), 837–844.
56. Diab, D.L., Yerian, L., Schauer, P., et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 24 (2009), 564–568.
57. Joka, D., Wahl, K., Moeller, S., et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 55 (2012), 455–464.
58. Kawanaka, M., Nishino, K., Nakamura, J., et al. Correlation between serum cytokeratin -18 and the progression or regression of non-alcoholic fatty liver disease. Ann Hepatol 14:6 (2015), 837–844.
59. Cusi, K., Chang, Z., Harrison, S., et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with nonalcoholic fatty liver disease. J Hepatol 60:1 (2014), 167–174.
60. Shen, J., Chan, H.L., Wong, G.L., et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 56 (2012), 1224–1229.
61. Younossi, Z.M., Jarrar, M., Nugent, C., et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 18 (2008), 1430–1437.
62. Poynard, T., Ratziu, V., Charlotte, F., et al. Diagnostic value of biochemical markers (NASHTest) for the prediction of nonalcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6:34 (2006), 1–16.
63. Tamimi, T.I., Elgouhari, H.M., Alkhouri, N., et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 54 (2011), 1224–1229.
64. Dixon, J.B., Bhathal, P.S., O'Brien, P.E., Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121 (2001), 91–100.
65. Palekar, N.A., Naus, R., Larson, S.P., et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 26 (2006), 151–156.
66. Gholam, P.M., Flancbaum, L., Machan, J.T., et al. Nonalcoholic fatty liver disease in severely obese patients. Am J Gastroenterol 102 (2007), 399–408.
67. Younossi, Z.M., Page, S., Rafiq, N., et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 21 (2011), 431–439.
68. Anty, R., Iannelli, A., Patouraux, S., et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 32 (2010), 1315–1322.
69. Goodman, Z.D., Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 47:4 (2007), 598–607.
70. Williams, A.L., Hoofnagle, J.H., Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 95 (1988), 734–739.
71. Piperno, A., Sampietro, M., Pietrangelo, A., et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology 144 (1998), 996–1002.
72. Hartley, J.L., Brown, R.M., Tybulewicz, A., et al. Hyaluronic acid predicts hepatic fibrosis in children with hepatic disease. J Pediatr Gastroenterol Nutr 43 (2006), 217–221.
73. Kaneda, H., Hashimoto, E., Yatsuji, S., et al. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 21 (2006), 1458–1465.
74. Suzuki, A., Angulo, P., Lymp, J., et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 25 (2005), 779–786.
75. Yoneda, M., Mawatari, H., Fujita, K., et al. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol 42 (2007), 375–381.
76. Sakugawa, H., Nakayoshi, T., Kobashigawa, K., et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 11 (2005), 255–259.
77. Yoneda, M., Uchiyama, T., Kato, S., et al. Plasma pentraxin 3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol 8:53 (2008), 1–9.
78. Angulo, P., Hui, J.M., Marchesini, G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007), 846–854.
79. Ratziu, V., Massard, J., Charlotte, F., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6:6 (2006), 1–13.
80. Harrison, S.A., Oliver, D., Arnold, H.L., et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57 (2008), 1441–1447.
81. Cales, P., Laine, F., Boursier, J., et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 26 (2011), 1536–1543.
82. McPherson, S., Stewart, S.F., Henderson, E., et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59 (2010), 1265–1269.
83. Ratziu, V., Giral, P., Charlotte, F., Liver fibrosis in overweight patients. Gastroenterology 118 (2000), 1117–1123.
84. Rosenberg, W.M., Voelker, M., Thiel, R., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127 (2004), 1704–1713.
85. Younossi, Z.M., Baranova, A., Ziegler, K., et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42 (2005), 665–674.
86. Bell, L.N., Theodorakis, J.L., Vuppalanchi, R., et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 51:1 (2010), 111–120.
87. Lim, J.W., Dillon, J., Miller, M., Proteomic and genomic studies of non-alcoholic fatty liver disease - clues in the pathogenesis. World J Gastroenterol 20:26 (2014), 8325–8340.
88. Charlton, M., Viker, K., Krishnan, A., et al. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology 49:4 (2009), 1375–1384.
89. Rodriguez-Suarez, E., Duce, A.M., Caballeria, J., et al. Nonalcoholic fatty liver disease proteomics. Proteomics Clin Appl 4:4 (2010), 362–371.
90. Yu, C., Xu, C., Xu, L., et al. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 56 (2012), 241–247.
91. Ladaru, A., Balanescu, P., Stan, M., et al. Candidate proteomic biomarkers for non-alcoholic fatty liver disease (steatosis and non-alcoholic steatohepatitis) discovered with mass-spectrometry: a systematic review. Proteomics Clin Appl 4:4 (2010), 362–371.
92. Blomme, B., Francque, S., Trepo, E., et al. N-glycan based biomarker distinguishing nonalcoholic steatohepatitis from steatosis independently of fibrosis. Dig Liver Dis 44:4 (2012), 315–322.
93. Yamasaki, Y., Nouso, K., Miyahara, K., et al. Use of non-invasive serum glycan markers to distinguish nonalcoholic steatohepatitis from simple steatosis. J Gastroenterol Hepatol 30:3 (2015), 528–534.
94. Pirola, C.J., Fernandez, G.T., Castano, G.O., et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64:5 (2015), 800–812.
95. Mehta, R., Otgonsuren, M., Younoszai, Z., et al. Circulating miRNA in patients with nonalcoholic fatty liver disease and coronary artery disease. BMJ Open Gastroenterol, 3(1–7), 2016, e000096.
96. Yamada, H., Suzuki, K., Ichino, N., et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 424 (2013), 99–103.
97. Castera, L., Forns, X., Alberti, A., Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48 (2008), 835–847.
98. Afdhal, N.H., Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N Y) 8:9 (2012), 605–607.
99. Sandrin, L., Fourquet, B., Hasquenoph, J.M., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29:12 (2003), 1705–1713.
100. Mueller, S., Sandrin, L., Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med 2 (2010), 49–67.
101. Fraquelli, M., Rigamonti, C., Casazza, G., et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 56 (2007), 968–973.
102. Roulot, D., Czernichow, S., Le Clésiau, H., et al. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 48 (2008), 606–613.
103. Boursier, J., Konate, A., Gorea, G., et al. Reproducibility of liver stiffness measurement by ultrasonographic elastometry. Clin Gastroenterol Hepatol 6 (2008), 1263–1269.
104. ®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - where do we stand?. World J Gastroenterol 22:32 (2016), 7236–7251.
105. Wilder, J., Patel, K., The clinical utility of FibroScan as a noninvasive diagnostic tests for liver disease. Med Devices (Auckl) 7 (2014), 107–114.
106. Castera, L., Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 142 (2012), 1293–1302.
107. de Ledinghen, V., Douvin, C., Kettaneh, A., et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus–coinfected patients. J Acquir Immune Defic Syndr 41:2 (2006), 175–179.
108. Sanchez, A.G., Garcia, P.F., Vallecillo, M.A., et al. FibroScan evaluation of liver fibrosis in liver transplantation. Transplant Proc 41:3 (2009), 1044–1046.
109. Friedrich-Rust, M., Ong, M.F., Martens, S., et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 134 (2008), 960–974.
110. Talwalkar, J.A., Kurtz, D.M., Schoenleber, S.J., et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systemic review and meta-analysis. Clin Gastroenterol Hepatol 5 (2007), 1214–1220.
111. Tsochatzis, E.A., Gurusamy, K.S., Ntaoula, S., et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 54 (2011), 650–659.
112. Awad, M.D., Shiha, G.E., Sallam, F.A., et al. Evaluation of liver stiffness measurement by Fibroscan as compared to liver biopsy for assessment of hepatic fibrosis in children with chronic hepatitis C. J Egypt Soc Parasitol 43:3 (2013), 805–819.
113. Afdhal, N.H., Bacon, B.R., Patel, K., et al. Accuracy of Fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol 13:4 (2015), 772–779.
114. Foucher, J., Chanteloup, E., Vergniol, J., et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55:3 (2006), 403–408.
115. Coco, B., Oliveri, F., Maina, A.M., et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 14 (2007), 360–369.
116. Arena, U., Vizzutti, F., Corti, G., et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 47 (2008), 380–384.
117. Hopper, I., Kemp, W., Porapakkham, P., et al. Impact of heart failure and changes to volume status on liver stiffness: non-invasive assessment using transient elastography. Eur J Heart Fail 14 (2012), 621–627.
118. Yashima, Y., Tsujino, T., Masuzaki, R., et al. Increased liver elasticity in patients with biliary obstruction. J Gastroenterol 46 (2011), 86–91.
119. Kettaneh, A., Marcellin, P., Douvin, C., et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 46:4 (2007), 628–634.
120. Foucher, J., Castera, L., Bernard, P.H., et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol 18:4 (2006), 411–412.
121. Castera, L., Foucher, J., Bernard, P.H., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51:3 (2010), 828–835.
122. Hashemi, S.A., Alavian, S.M., Gholami-Fesharaki, M., Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Caspian J Intern Med 7:4 (2016), 242–252.
123. Boursier, J., Vergniol, J., Guillet, A., et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol 65:3 (2016), 570–578.
124. Kleiner, D.E., Brunt, E.M., Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 32 (2012), 3–13.
125. Ryan, C.K., Johson, L.A., Germin, B.I., et al. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 8 (2002), 1114–1122.
126. Palmentieri, B., deSio, I., La Mura, V., et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 38 (2006), 485–489.
127. Sasso, M., Miette, V., Sandrin, L., et al. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan®. Clin Res Hepatol Gastroenterol 36 (2012), 13–20.
128. de Lédinghen, V., Vergniol, J., Foucher, J., et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 32 (2012), 911–918.
129. Karlas, T., Petroff, D., Garnov, N., et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One, 9(3), 2014, e91987.
130. Sasso, M., Beaugrand, M., de Ledinghen, V., et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 36:11 (2010), 1825–1835.
131. Petta, S., Wong, V.W., Cammà, C., et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology 65:4 (2017), 1145–1155.
132. Myers, R.P., Pollett, A., Kirsch, R., et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 32 (2012), 902–910.
133. Chan, W.K., Mustapha, N., Raihan, N., et al. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 29 (2014), 1470–1476.
134. de Ledinghen, V., Wong, G.L., Vergniol, J., et al. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 31:4 (2016), 848–855.
135. Festi, D., Schiumerini, R., Marzi, L., et al. The diagnosis of non-alcoholic fatty liver disease–availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 37 (2013), 392–400.
136. Dyson, J.K., Anstee, Q.M., McPherson, S., Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Liver 5:3 (2013), 211–218.
137. Singh, S., Venkatesh, S.K., Loomba, R., et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol 26:5 (2016), 1431–1440.
138. Imajo, K., Kessoku, T., Honda, Y., et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver than transient elastography. Gastroenterology 150:3 (2016), 626–637.